Oral candidate shows favourable safety profile and signs of clinical activity in NPDR More: Strong clinical data for Breye lead asset danegaptide Source: News
read more
Recognising the achievements of this year’s standout healthcare collaborations More: EHP Awards triumph Source: News
read moreOn top of 348 known job cuts across the organization last year, Genentech laid off an additional 141 staffers last August that are just now being disclosed. More: Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals
read moreAs the 2026 Winter Olympics get underway in Italy this week, Eli Lilly—a partner of both Team USA and the Milan Cortina Games as a whole—is rolling out a new corporate campaign inspired by the event. More: Lilly likens relentless
read moreBiogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees positive signs with the recent launch of its high-dose version of the spinal muscular atrophy treatment in Japan. More: Biogen pins
read moreThe stock price of BridgeBio plunged 15% Thursday on Pfizer’s reported decision to withdraw a tafamidis patent in the EU, triggering fears of earlier generic entry in the blockbuster ATTR-CM market. More: BridgeBio shares slide as Pfizer's tafamidis patent revoked
read more© 1994 - 2026 B.M. Pharmaceuticals